期刊
CANCER INVESTIGATION
卷 30, 期 3, 页码 231-235出版社
INFORMA HEALTHCARE
DOI: 10.3109/07357907.2012.656862
关键词
Angiogenesis; Cancer biomarkers; Non-small cell lung cancer; Clinical trials; VEGF
类别
资金
- Breathe California
- Colombo Trust (HW)
- NIH [1 R01 HL074267-01]
We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL (p = .01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p = .38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据